Anbogen Therapeutics, Inc.

7784 · TPEx

Public Market Listing

7784TPEx

TPEx primary exchange listing

Live quotes, historical charts, and market capitalization for Anbogen Therapeutics, Inc. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
EGFR / HER2 exon 20 mutationsSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
GozanertinibPhase 1/2Advanced Solid Tumor, Non Small Cell Lung Cancer, HER2 Mutations
Est. primary completion 2026-11 · NCT05532696 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.